Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580938 | 0.83 | MAPT (0.46) | MAPTALDH1A1KMT2APOLBGLA | |
| SCHEMBL13728103 | 0.83 | MAPT (0.46) | MAPTALDH1A1KMT2APOLBGLA | |
| SCHEMBL8771567 | 0.83 | KMT2A (0.50) | MAPTALDH1A1KMT2APOLBGLA | |
| SCHEMBL22556903 | 0.83 | ALDH1A1 (0.43) | MAPTALDH1A1KMT2ACRHBPCRHR2 | |
| SCHEMBL28661618 | 0.80 | PKM (0.47) | MAPTALDH1A1KMT2AGLAHTT | |
| SCHEMBL20568542 | 0.80 | ALDH1A1 (0.49) | MAPTALDH1A1KMT2APOLBGLA | |
| SCHEMBL29180861 | 0.80 | MAPT (0.45) | MAPTALDH1A1KMT2APOLBGLA | |
| SCHEMBL23146879 | 0.79 | DPP4 (0.40) | MAPTALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL16522671 | 0.76 | KMT2A (0.47) | MAPTALDH1A1KMT2APOLBGLA | |
| SCHEMBL1626031 | 0.76 | ALDH1A1 (0.51) | MAPTALDH1A1KMT2ACRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4034532-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | Exelixis, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021062245-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | EXELIXIS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | MAPT 2493/4885ALDH1A1 4282/4885KMT2A 3773/4885 |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | MAPT 2493/4885ALDH1A1 4282/4885KMT2A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.